Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III trial of rifaximin (L-105) in pediatric hepatic encephalopathy
jRCT2080224978Phase 3Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rifaximin in hepatic encephalopathy (HE) and hyperammonemia, sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Started Dec 2019; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)hyperammonemia
Beyond the preview
Go deeper on jRCT2080224978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224978.